Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
Regulatory Filings Classification · 75% confidence The document is a press release by Inventiva announcing that its CEO will present at the 2026 Jefferies Global Healthcare Conference. It does not contain financial results, detailed presentation slides, proxy materials, or other report content. It is an announcement of an upcoming investor outreach event, which does not fit any specialized category. Therefore, it falls into the fallback category for miscellaneous regulatory/press announcements.
2026-05-21 French
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Regulatory Filings Classification · 25% confidence The document is a press release announcing that the company’s CEO will present at an upcoming healthcare conference. It does not contain substantive financial data nor is it an actual investor slide deck or detailed report. It is an event notice that doesn’t fit into specialized categories like earnings release, management change, capital update, or investor presentation. Therefore it falls under the general regulatory announcement fallback category.
2026-05-21 English
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the presentation of scientific abstracts at the EASL Congress 2026. It contains no financial statements, no report attachments, no management or board changes, and is not a regulatory form itself. There is no fitting specific category, so under the fallback it is classified as a general regulatory announcement (RNS).
2026-05-13 French
Inventiva to Present Abstracts at the EASL Congress 2026
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing presentation of scientific abstracts at a medical conference. It contains no financial results, no regulatory compliance statements, no earnings or annual report data, no board or management changes, no capital/investment details. It is a generic corporate announcement and does not fit any specific category, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-13 English
Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor
Board/Management Information Classification · 90% confidence The document is a press release announcing the appointment of three senior executives (CFO, General Counsel, HR Director) and the reassignment of two existing executives. There is no financial data or investor presentation; it is clearly an announcement of management changes. This fits the Board/Management Information category (MANG).
2026-04-22 French
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Board/Management Information Classification · 91% confidence The document is a press release announcing the recruitment of a new Chief Financial Officer, Chief Legal Officer, and Chief People Officer, i.e., changes in the company’s senior management team. This clearly matches “Board/Management Information” rather than a financial report, earnings release, or other category.
2026-04-22 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.